Literature DB >> 24401573

Current venous thromboembolism management and outcomes in Japan.

Mashio Nakamura1, Tetsuro Miyata, Yasushi Ozeki, Morimasa Takayama, Kimihiro Komori, Norikazu Yamada, Hideki Origasa, Hirono Satokawa, Hideaki Maeda, Nobuhiro Tanabe, Naoki Unno, Takashi Shibuya, Kazuo Tanemoto, Katsuhiro Kondo, Tetsuhito Kojima.   

Abstract

BACKGROUND: Epidemiology and clinical management of acute venous thromboembolism (VTE) are not readily available in Japan. METHODS AND
RESULTS: The Japan VTE Treatment Registry (JAVA) is a multicenter cohort study of consecutive patients with an objectively confirmed, symptomatic acute pulmonary embolism (PE), symptomatic acute deep vein thrombosis (DVT), or asymptomatic acute proximal DVT. Of the 1,076 patients enrolled with acute VTE, 68.7% presented with an isolated DVT; 17.0% had PE alone; and 14.4% had both. VTE management was characterized by a high rate of inferior vena cava filter insertion (40.6%), frequent thrombolysis (21.1%), and sub-therapeutic unfractionated heparin-based anticoagulation, followed by warfarin prescription, mostly targeting an international normalized ratio of 2.0 (range, 1.5-2.5). During a mean observation period of 252.5 days, 29 recurrent cases of VTE were documented, yielding an incidence rate of 3.9 per 100 patient-years. A total of 123 patients died during the study period, corresponding to a rate of 16.6 deaths per 100 patient-years. The incidence of major bleeding was 3.2% per patient-year, including 2 fatal hemorrhages and 7 intracranial hemorrhages.
CONCLUSIONS: VTE management in Japan is characterized by a highly aggressive strategy in the acute phase, in contrast to protocols that use low-level anticoagulation. The VTE recurrence rates in Japan and Western countries are similar, but mortality is higher in Japan, with significant variability depending on patient and management characteristics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24401573     DOI: 10.1253/circj.cj-13-0886

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  30 in total

1.  Burden of cardiovascular disease in Japanese cancer patients and survivors: a single cancer-center study in Niigata City.

Authors:  Yuji Okura; Tsugumi Takayama; Kazuyuki Ozaki; Hiroshi Tanaka; Hiroshi Seki; Tatsuya Takenouchi; Nobuaki Sato; Tohru Minamino
Journal:  Int J Clin Oncol       Date:  2018-09-14       Impact factor: 3.402

2.  Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide.

Authors:  Atsushi Isoda; Naru Sato; Yuri Miyazawa; Yoshinobu Matsumoto; Mina Koumoto; Masahito Ookawa; Morio Sawamura; Morio Matsumoto
Journal:  Int J Hematol       Date:  2015-07-16       Impact factor: 2.490

3.  Cryptogenic stroke prevention through venous thromboembolism prevention: Potential and truth in the advent of non-vitamin K antagonist oral anticoagulants.

Authors:  Kengo Ayabe; Shinya Goto
Journal:  J Cardiol Cases       Date:  2016-07-16

4.  A Caprini Risk Score-Based Cost-Effectiveness Analysis of Enoxaparin for the Thromboprophylaxis of Patients After Nonorthopedic Surgery in a Chinese Healthcare Setting.

Authors:  Yun Bao; Gang Zhao; Shuli Qu; Tengbin Xiong; Xingxing Yao; Bin Wu
Journal:  Clin Drug Investig       Date:  2020-02       Impact factor: 2.859

5.  Cost Effectiveness of Apixaban and Enoxaparin for the Prevention of Venous Thromboembolism After Total Knee Replacement in China.

Authors:  Xiaoyu Yan; Xiaohua Gu; Lei Zhou; Houweng Lin; Bin Wu
Journal:  Clin Drug Investig       Date:  2016-12       Impact factor: 2.859

6.  Indications, applications, and outcomes of inferior vena cava filters for venous thromboembolism in Japanese patients.

Authors:  Yugo Yamashita; Takashi Unoki; Daisuke Takagi; Yasuhiro Hamatani; Mitsuru Ishii; Moritake Iguchi; Hisashi Ogawa; Nobutoyo Masunaga; Hiromichi Wada; Koji Hasegawa; Mitsuru Abe; Masaharu Akao
Journal:  Heart Vessels       Date:  2015-07-02       Impact factor: 2.037

7.  Epidemiological and outcome data in Japanese patients with deep vein thrombosis with and without malignancy.

Authors:  Kensuke Yokoi; Masahiko Hara; Yasunori Ueda; Keiichi Yamamoto; Keiko Ota; Daijiro Kabata; Tetsuhisa Kitamura; Yasushi Sakata; Ayumi Shintani
Journal:  Heart Vessels       Date:  2017-07-24       Impact factor: 2.037

8.  Treatment Strategy for Cancer-associated Venous Thromboembolism During Chemotherapy: The Keep ACT2 Concept.

Authors:  Yoshihiro Tanaka; Yuta Sato; Tomonari Suetsugu; Junichi Mase; Ritsuki Takaha; Naoki Okumura; Nobuhisa Matsuhashi; Takao Takahashi; Kazuhiro Yoshida
Journal:  Cancer Diagn Progn       Date:  2021-11-03

9.  Clinicopathological Characteristics of Cancer-Associated Venous Thromboembolism (CAT-VTE) from a Medicolegal Autopsy.

Authors:  Ayako Ro; Norimasa Kageyama; Toshiji Mukai
Journal:  Ann Vasc Dis       Date:  2022-06-25

10.  Successful treatment of a massive pulmonary embolism using rivaroxaban in a patient with antithrombin III deficiency.

Authors:  Junji Yamaguchi; Nobuhiro Hara; Tetsuo Yamaguchi; Yasutoshi Nagata; Toshihiro Nozato; Takamichi Miyamoto
Journal:  J Cardiol Cases       Date:  2017-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.